GSK (GSK) closed at $50.75 on Oct 23, 2026, down 0.9% on the day. The stock is up 2.2% over the past month, down 2.4% over three months, up 4.3% year to date and up 16.6% over the past year. It trades 17.1% below its 52-week high of $61.21 and 20.3% above its 52-week low of $42.18. The close sits above its 50-day moving average ($49.57) and below its 200-day moving average ($52.30).
NextPick tracks GSK in its Pharma basket alongside JNJ, ABBV, RHHBY, MRK and NVS. As of Oct 23, 2026, the basket's money-flow score is 0 (neutral), and the basket is up 2.1% over five sessions. Over the past month GSK ranks 8th of 12 basket members by price change.
GSK is scheduled to report earnings on Oct 28, 2026, before market open.
GSK options were pricing 31% at-the-money implied volatility on Oct 16, 2026, an IV rank of 70 over the past year.
GSK is scheduled to report on Oct 28, 2026, before market open.
No — the Oct 23, 2026 close of $50.75 is 3.0% below the 200-day average of $52.30.
GSK closed 17.1% below its 52-week high of $61.21.
NextPick groups GSK with JNJ, ABBV, RHHBY, MRK and NVS in its Pharma basket.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
